For patients doing well on targeted therapies (alectinib, osimertinib) for metastatic NSCLC, what data / guidelines do you use to decide about holding treatment before/after surgical procedures?

Topics: Thoracic Malignancies • Medical Oncology

Answer from: Medical Oncologist at Community Practice

We know agents targeting VEGF can impact wound healing and should be held before and after surgery. There is no clear data for agents targeting EGFR, ALK, ROS1 and BRAF. Due to the risk of disease flare for patients holding targeted therapy I would consider this on a case by case basis and be very f...

Related Questions